Abbott Laboratories
NYSE:ABT

Watchlist Manager
Abbott Laboratories Logo
Abbott Laboratories
NYSE:ABT
Watchlist
Price: 117.76 USD 0.43% Market Closed
Market Cap: 204.3B USD
Have any thoughts about
Abbott Laboratories?
Write Note

Abbott Laboratories
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Abbott Laboratories
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Abbott Laboratories
NYSE:ABT
Long-Term Debt
$13.1B
CAGR 3-Years
-9%
CAGR 5-Years
-6%
CAGR 10-Years
13%
Becton Dickinson and Co
NYSE:BDX
Long-Term Debt
$17.9B
CAGR 3-Years
2%
CAGR 5-Years
0%
CAGR 10-Years
17%
Boston Scientific Corp
NYSE:BSX
Long-Term Debt
$9.2B
CAGR 3-Years
2%
CAGR 5-Years
-1%
CAGR 10-Years
8%
Edwards Lifesciences Corp
NYSE:EW
Long-Term Debt
$597.5m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Stryker Corp
NYSE:SYK
Long-Term Debt
$13.3B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
15%
Intuitive Surgical Inc
NASDAQ:ISRG
Long-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Abbott Laboratories
Glance View

Market Cap
204.9B USD
Industry
Health Care

Abbott Laboratories, a global leader in the healthcare industry, has a storied history dating back to its founding in 1888 by Dr. Wallace Abbott. The company is renowned for its dedication to improving health through innovative products that span several key segments: diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. With a robust portfolio that includes cutting-edge technologies such as continuous glucose monitoring systems and rapid COVID-19 tests, Abbott has positioned itself as a vital player in both consumer and professional healthcare arenas. Its commitment to research and development, capturing nearly $2 billion in annual investment, underscores the company's strategic focus on innovation and long-term growth, making it an attractive option for investors seeking stability and upward trajectory in the healthcare sector. Abbott's diverse product offerings and strong market presence provide a solid foundation for its financial performance, which has consistently demonstrated resilience and growth across economic cycles. The company's ability to adapt to changing healthcare needs—exemplified by its rapid response to the COVID-19 pandemic with the development of at-home testing solutions—highlights its proactive approach and operational agility. In addition to its impressive revenue streams, Abbott pays a growing dividend, appealing to income-focused investors. With a clear vision for the future, bolstered by global expansion and strategic acquisitions, Abbott Laboratories is not just a company that manufactures healthcare products; it is a catalyst for positive change in health and well-being, making it a compelling investment opportunity for those looking to capitalize on the ever-evolving healthcare landscape.

ABT Intrinsic Value
100.13 USD
Overvaluation 15%
Intrinsic Value
Price

See Also

What is Abbott Laboratories's Long-Term Debt?
Long-Term Debt
13.1B USD

Based on the financial report for Sep 30, 2024, Abbott Laboratories's Long-Term Debt amounts to 13.1B USD.

What is Abbott Laboratories's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
13%

Over the last year, the Long-Term Debt growth was -9%. The average annual Long-Term Debt growth rates for Abbott Laboratories have been -9% over the past three years , -6% over the past five years , and 13% over the past ten years .

Back to Top